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Abstract
The TNF family ligands BAFF/BLyS and APRIL play important roles in the homoestasis
and function of B cells. BAFF binds to the receptors BAFF-R/BR3, BCMA and TACI,
whereas APRIL interacts with BCMA, TACI and sulfated side chains of proteoglycans.
BAFF and APRIL are initially synthetized as membrane-bound proteins that can be
released into soluble forms by proteolytic processing. Both cytokines display the
characteristic homotrimeric structure of the TNF family, but BAFF is further able to
oligomerize under certain conditions into a virus-like particle containing twenty trimers.
All three receptors for BAFF are smaller than canonical TNF receptors and form compact
but extensive interactions with the ligands. Similarities and differences in these
interactions account for the observed binding specificities to BAFF and APRIL. In
contrast to TACI and BCMA, proteoglycans interact with APRIL at distinct sites and
may serve to concentrate APRIL at defined anatomical locations. Multimeric forms of
BAFF and APRIL are required for signaling through TACI, whereas BAFF-R responds
to all forms of BAFF, suggesting that the many different types of BAFF and APRIL may
be functionally relevant to control distinct aspects of their biology.
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1. Introduction
The cytokines B cell Activating Factor of the TNF Family (BAFF, also known as BLyS
or TALL-1) and A PRoliferation Inducing Ligand (APRIL) regulate several aspects of B
cell function and homeostasis. BAFF-deficient mice have little mature B cells in the
periphery and impaired humoral responses, whereas BAFF transgenic mice present with
B cell hyperplasia, hyperglobulinemia and autoimmunity (1-3). The phenotype of
APRIL-deficient mice is less severe, with deficient IgA responses to mucosal
immunization, whereas APRIL transgenic mice have elevated IgA levels and can develop
chronic lymphoblastic leukemia-like tumors derived from the B1 B cell population (4, 5).
BAFF binds to three receptors, BAFF-R, BCMA and TACI, whereas APRIL binds
BCMA and TACI only (reviewed in (6, 7)) (Figure 1). The phenotype of BAFF-R-
deficient mice is similar to that of BAFF-null mice, with marked decrease of mature B
cells (8, 9). BCMA-null mice are essentially normal, but with impaired survival of bone
marrow plasma cells (10). Finally, TACI is essential for humoral responses to T-
independent type-2 antigens, but also display B cell hyperplasia, indicating that TACI
exerts a negative role on the peripheral B cell population (11-13). It is unclear whether
the negative role of TACI on B cells is direct or indirect.
In human, mutations in TACI are found in about 8% of patients with common variable
immunodeficiency, a condition characterized by low antibody levels and susceptibility to
infections (14-17). BAFF is also an essential B cells survival factor in birds, although
BAFF-producing cells are different in birds and mammals (18). Curiously, APRIL
appears to be missing in birds. In contrast, fishes do not only express BAFF and APRIL,
but also a third related ligand named BALM (for BAFF-APRIL-like molecule), which is
absent in mammals (19).
In the present chapter, structural aspects of BAFF, APRIL and their receptors will be
reviewed.
2. Multiple forms of BAFF and APRIL
BAFF and APRIL are remarkable by the diversity of their mature forms that result both
from splicing and post-translational events. The numerous splice variants have been
reviewed previously (7). Briefly, delta-BAFF lacks exon 3 and acts as a dominant
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negative inhibitor of the active full-length form (20). Similar exon skipping events occur
in human APRIL, but their functional impacts have not been characterized. Moreover, an
intergenic splicing between tweak and april genes generate TWE-PRIL, a hybrid ligand
containing the full receptor-binding domain of APRIL (21) (Figure 1). Finally, the use of
an alternative splice acceptor site generates two isoforms of mouse APRIL differing by
just one amino acid (Ala120). These two isoforms only display subtle differences in
receptor binding, and the shorter isoform does not exist in human (22).
BAFF and APRIL are both synthesized as membrane-bound proteins that can be
processed to soluble forms by proteolytic processing at a furin consensus site (23, 24)
(Figure 2). APRIL is efficiently processed within the cell, and whether APRIL can be
expressed as a membrane-bound form remains to be demonstrated (25). However, TWE-
PRIL was suggested to exist in a membrane-bound form (21).
Soluble BAFF can assemble as virus-like particles (26), and soluble APRIL can bind to
proteoglycans (27, 28) (Figure 1). Formation of BAFF-APRIL heteromers has also been
reported in sera of patients with rheumatoid arthritis (29).
3. Structure of BAFF and APRIL
3.1. Structural comparison with other of TNF family members
TNF and related ligands assemble as homotrimers (30), and BAFF and APRIL are no
exception to the rule (31-33) (Figure 3). Each APRIL and BAFF protomers are composed
of two β-sheets containing strands A’AHCF and B’BGDE. Strands A, C, E, F and H are
the most conserved and form much of the trimer interface. This interface is rich in
hydrophobic interactions that appear to be the main forces driving trimer formation. The
B’BGDE sheet is more solvent exposed and most of its strands are less conserved in
sequence among different TNF family ligands (30). BAFF and APRIL have an internal
disulfide bridge linking strands E and F (Figure 2). This later feature is shared with the
TNF family ligands BALM, EDA and Tweak.
3.2. BAFF forms virus-like particles
In some studies, BAFF crystallized as a virus-like particle containing 20 trimers (26, 34,
35). The BAFF 60-mer contains 3-fold symmetry axes corresponding to those of each
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BAFF 3-mer, but also 5-fold symmetry axes (Figure 4; colored ring of 5 BAFF 3-mers).
In this structure, BAFF trimers interact with each other through extended sets of
interactions involving the unusually long DE-loop, also known as the “flap”. There are
numerous interactions in this region involving salt bridges and hydrophobic interactions
(Figure 4, lower panels). In one published structure, two citrate and three magnesium ions
interact with the portion of the flap facing the inside of the 60-mer structure (32). The
flap and most of the key residues involved in trimer-trimer interactions are conserved in
BAFF from vertebrates (Figure 2). These features are not conserved in APRIL, BALM
and other TNF family members (Figure 2). The high number of charged interactions
required for BAFF 60-mer assembly explains the acid-sensitivity of this structure (26, 36)
and the different outcome of crystallization performed at acidic or neutral pH (26, 32, 33,
37). Mutation of His218 to Ala entirely prevented 60-mer formation in human BAFF
(36).
3.3. APRIL binds to proteoglycans
Proteoglycans are heavily glycosylated O-linked glycoproteins that are either soluble or
membrane-bound (38). They have extended, negatively charged oligosaccharide side
chains collectively designated glycosaminoglycans. Negative charges originate from
anionic monosaccharides (such as glucuronic or iduronic acids) and from more or less
extensive sulfation events. Heparin is a protein-free glycosaminoglycan of the heparan
sulfate type.
Human and mouse APRIL contain a short basic amino acid sequence preceding β-strand
A (Figure 2). This basic sequence, which is absent in BAFF, is required but not sufficient
to bind heparin and proteoglycans (27, 28). Additional basic residues scattered on the
same surface of APRIL are also required for binding to heparin (27).  It is therefore likely
that negatively charged glycosaminoglycans bind to a basic surface of APRIL, as
illustrated in the model shown in Figure 5. It is noteworthy that the proteoglycan-binding
site of APRIL is clearly distinct from the binding sites of TACI and BCMA (Figure 5).
4. Receptor binding
4.1. Structure of BCMA, TACI and BAFF-R
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TNF receptor family members are generally type I transmembrane proteins with cystein-
rich domains (CRDs) in their extracellular domains. These CRDs can be further divided
into small structural units called modules (30). For example, TNF-R1 contains 4 CRDs
corresponding to a total of eight modules. BCMA, TACI and BAFF-R differ significantly
form canonical TNF receptors. First, they are type III trans-membrane proteins lacking a
signal peptide. Second, TACI contains two CRDs, BCMA has only one and BAFF-R has
just no canonical CRD. Third, they contain a module not present in other TNF receptors
and thus are not easy to recognize as such based on the primary sequence only. BAFF-R,
BCMA and TACI share a structurally conserved β-hairpin (corresponding to module A1
of the third CRD of TNF-R1) immediately followed by a short, one turn helix (Figure 6).
This determines much of the ligand binding properties. After these conserved structural
features, receptors diverge: TACI and BCMA have an additional helix, but that adopt
different orientations (39) (Figure 7). The second module of BAFF-R is truncated and the
one remaining cystein residue at the end of the one turn helix pairs with another cystein
residue in the β-hairpin (Figure 6).
TACI is remarkable in that it contains 2 CRDs that probably arose from exon duplication
(39). CRD2 binds BAFF and APRIL with high affinity, whereas CRD1 also binds, but
with low affinity. In human, a short form of TACI lacking CRD1 is produced by
alternative splicing (39) (Figure 1). It is noteworthy that TACI, like APRIL, binds to
proteoglycans (40) (Figure 1). The site of this interaction has not been mapped.
4.2. Comparison of ligand-receptor binding in the TNF family
The TNF receptor family members TNF-R1, OX40 and DR5 are elongated proteins that
contact their ligands at the interface between two protomers (41-44) (Figure 8). The
interaction extends over the entire length of the ligand and involves residues of both
ligand protomers (Figure 8). In contrast, the contact site of BAFF-R on BAFF is localized
and involves mainly a single BAFF protomer (Figure 8). The same is true for BCMA and
TACI binding to BAFF and APRIL (Figure 8). The surface buried by interaction with an
extended receptor (like TNF-R1) or a compact receptor (like BAFF-R) is approximately
the same, so that both types of interaction can be of high affinity. As mentioned above,
the binding of BCMA or TACI to APRIL does not overlap with the proteoglycan-binding
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site of APRIL (Figure 5). In BAFF 60-mer, the receptor binding sites remain accessible
on the outer surface of the virus-like cluster (Figure 4). In this structure however, the
receptor-binding pocket of BAFF is delimitated by the flap region of the neighboring
BAFF trimer, raising the question of how the long form of TACI does bind this structure.
If the CRD1-CRD2 junction of TACI is flexible enough, the high affinity CRD2 will
probably bind BAFF 60-mer. If this junction is rigid, only the low affinity CRD1 of
TACI may have access to the binding site.
4.2. Structural determinants of binding specificity
The β-hairpins of BCMA, BAFF-R and TACI contain conserved aspartate and leucine
residues known as the DxL motif (Figure 6). A synthetic, constrained peptide containing
just 6 residues of BAFF-R hairpin, including the DxL motif, is sufficient for BAFF
binding (45). In an experimental procedure called shotgun alanine scanning, residues of
the receptors were systematically screened for their contribution to ligand binding (37,
39, 46). This method takes into account the potentially confounding effect of decreased
expression of mutant receptors, and detects whether a given residue if beneficial, neutral
or detrimental for the interaction. As expected, mutations of the DxL motif abolished
binding. Other important residues were ligand-dependent. For example, binding to
APRIL requires an aromatic residue in the hairpin (F78 of TACI; Y13 of BCMA), which
is not required for BAFF binding (Figure 7). This residue is absent in BAFF-R that does
not bind APRIL.  Conversely, an arginine residue in the hairpin favors binding to BAFF,
but is not required for binding to APRIL (R30 of BAFF-R; R84 of TACI). BCMA, which
binds BAFF with low affinity, has a suboptimal residue in this position (H19). The one
turn helix following the hairpin is also important in determining the specificity of the
interactions. APRIL requires an arginine at the end of this helix (R27 of BCMA),
whereas BAFF need a leucine (L38 of BAFF-R). Thus, L38 of BAFF-R favors BAFF
binding but prevents APRIL binding. Conversely, R27 of BCMA favors APRIL binding
and weakens BAFF binding. TACI adopts a different structure in this region, with P97
being the spatially corresponding residue that shows a preference for APRIL. In
summary, BCMA, TACI and BAFF-R have an intrinsic tendency to bind BAFF and
APRIL through the DxL motif, which is positively or negatively regulated in a ligand-
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dependent manner by various other residues. This explains the specificity of BAFF-R for
BAFF and the preferential binding of BCMA to APRIL.
This structural knowledge was exploited to prepare an APRIL-specific BCMA by
replacing a residue favorable for BAFF binding (I22) to one that enhances APRIL
binding (I22K) (46) (Figure 7). In another application, anti-BAFF-R antibodies were
selected by phage display on BAFF-R and submitted to affinity maturation in order to
recognize both human and mouse BAFF-R with high affinity (47). One such antibody
recognized the conserved DxL motif of BAFF-R, and shared several of its BAFF-R-
binding characteristics with BAFF. This antibody competed for BAFF binding and acted
as a BAFF-R antagonist. Administration of this antibody to mice depleted various B cell
populations by the dual mechanism of inhibiting BAFF signals and mediating antibody-
dependent cellular cytotoxicity (48). A similar but less marked effect was also observed
in non-human primates (48).
5. Receptor signaling
5.1. Signaling overview
BAFF-R mediates much of the BAFF survival signals required to maintain the peripheral
B cell population. BAFF can be functionally replaced for this purpose by the deletion of
TRAF2 or TRAF3, or by the constitutive activation of either canonical or non-canonical
NF-κB pathways (49-52). TRAF3 is the only known intracellular binding partner of
BAFF-R (53). TRAF3 also negatively regulates the kinase NIK, which is apical to the
non-canonical NF-κB pathway (54). This suggests that BAFF-R engagement interferes
with the negative function of TRAF3 on the NF-κB pathway, ultimately leading to the
activation of this pathway and its pro-survival effects.
5.2. TRAF binding
A natural mutation affecting the last 8 amino acids of BAFF-R in A/WySnJ mice almost
completely abolishes BAFF-R activity (55, 56). This mutation occurs close to a sequence
conserved in both BAFF-R and BCMA that mediates binding to TRAF3 (53), strongly
suggesting that TRAF3 regulates BAFF-R signaling. Indeed, mutation of the TRAF3-
binding sequence abolishes BAFF-R’s ability to engage non-canonical NF-κB (57).
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TRAF-binding sequences in the intracellular portions of TNF receptors are linear
peptides that usually bind either TRAF6, or TRAF1, 2, 3 and 5. The strict specificity of
BAFF-R for TRAF3 is therefore unusual, but the determinants for this specificity are now
well understood (57, 58). The C-terminal portion of TRAF3 adopts a mushroom-like
structure with the coiled-coil domain forming the stem and the homotrimeric TRAF-C
domain forming the cap (Figure 9). The TRAF-binding sequence of BAFF-R wraps
around the TRAF-C domain (58) (Figure 9). The overall similarity in size and symmetry
of the extracellular BAFF - BAFF-R complex and of the intracellular BAFF-R - TRAF3
complex is striking. How BAFF-R exerts functional changes on TRAF-3 upon
recruitment is not understood.
6. Oligomerization-dependent signaling
With the exception of delta-BAFF, whose transgenic over-expression demonstrated a
dominant negative effect on B cell homeostasis (20), little is known regarding the
physiological function of the various forms of BAFF and APRIL. The analysis of
chimearic mice expressing BAFF either in bone marrow-derived cells or in non-bone
marrow, radiation-resistant cells indicated that radiation-resistant cells can produce
sufficient amounts of BAFF for maintaining the peripheral B cell population, whereas
BAFF produced by bone marrow-derived cells may only provide a more local support to
B cells (59). In any case, this study demonstrated the existence of different sources of
BAFF with apparently different physiological effects. Whether various cell types produce
different forms of BAFF, such a membrane-bound or soluble BAFF, remains to be
studied.
A number of in vitro studies suggest that ligand oligomerization may modulate biological
activity. In the original report, BAFF 60-mer had a modest two-fold co-stimulatory effect
on human blood B cells that was not observed with a flap-deletion mutant (26). In mouse
B cells, BAFF 60-mer was only moderately more active than BAFF 3-mer at co-
stimulating B cell proliferation (36). The differential effects of BAFF 3-mer and 60-mer
were analyzed in more detail using mouse cells (60). The co-stimulatory effect of BAFF
did not rely on increased proliferation, but rather on increased B cell survival, consistent
with its relatively minor effects. Survival was the result of a mixed signal originating
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from both BAFF-R and TACI. Whereas BAFF-R could be stimulated by both BAFF 3-
mer and BAFF 60-mer, TACI responded exclusively to BAFF 60-mer or other
multimeric forms of BAFF. Thus, BAFF-mediated B cell co-stimulation is the result of
two distinct signals: one originating from BAFF-R in response to any form of BAFF, and
one originating from TACI in response to multimeric forms of BAFF (60). In
plasmablasts, BAFF-mediated survival depended on TACI with little contribution of
BAFF-R, and also required oligomeric forms of BAFF (60). In a similar way, TACI also
responded to cross-linked APRIL, but not to APRIL 3-mer (27, 60). Importantly, TACI
bound BAFF 3-mer and 60-mer equally well, but only signaled in response to the later. It
is possible that binding of BAFF 3-mer to TACI is sufficient to recruit a single trimeric
TRAF (see figure 9), which may not be able to signal as such. Indeed, cross-linking of
TRAF2 and TRAF6 is required for efficient activation of the NF-κB pathway (61).
Oligomeric forms of BAFF may allow signaling through TACI by enabling recruitment
of several TRAFs in close proximity.
Interestingly, survival of human monocytes ex vivo was enhanced by BAFF in a TACI-
dependent manner (62). This effect was only observed with some commercial BAFF
preparations but not others, although all of them supported B cell survival (62).  These
puzzling observations could be readily explained if the active preparations contained a
proportion of oligomeric BAFF able to signal through TACI. This difference would not
be detected on B cells that mainly respond through BAFF-R.
The finding that BAFF-R and TACI can respond to different forms of BAFF but transmit
similar survival signals can help explain the paradoxical role of TACI in B cell biology.
TACI-deficient mice indeed have impaired humoral responses despite their elevated B
cell number (12, 13). Plasmablasts elicited in response to T-independent type-2 antigens
appear to rely heavily on TACI for their survival (63), but cannot respond to BAFF 3-mer
for lack of BAFF-R. Thus, deletion of TACI would penalize plasmablasts without
preventing the majority of BAFF-R-expressing B cells to receive survival signals: these
may even receive more, as TACI-deficient mice have elevated levels of circulating BAFF
(60), leading to the observed enlargement of the B cell pool.
It is believed that APRIL is mainly released as a soluble cytokine (25). This form of
APRIL can however not activate TACI, and is also probably poorly active on BCMA
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(60). Soluble APRIL released in vivo accumulates on proteoglycans (64). It is tempting to
speculate that proteoglycan-bound APRIL is a biologically active form particularly
important to support survival of antibody secreting cells in specialized environments such
as the bone marrow or the intestinal mucosa (65, 66).
7. Conclusions and open questions
From a structural point of view, the BAFF - APRIL system is certainly one of the best
characterized within the TNF family. Taken together, structural studies on BAFF, APRIL
and their receptors have provided three highly unexpected surprises. The first one was the
unique mode of receptor binding on a single ligand protomer, the second one was the
discovery of the oligomeric form of BAFF 60-mer and the third one was the interaction
of APRIL and TACI with glycosaminoglycans.  These studies have not only provided a
detailed molecular basis for the observed binding specificities between ligands and
receptors, but also hinted at different mechanisms of action of trimeric and oligomeric
BAFF and APRIL. The remaining open questions regarding structure are relatively few.
They include the mapping of the proteoglycan binding site(s) of TACI, the mode of
binding of full length TACI on BAFF 60-mer, the structural impact of exon 3 deletion in
BAFF and the possibility of ligand-independent pre-association of TACI.
The analysis of receptor-deficient mice has taught us a lot on the role of these different
receptors. However, little is known on the relative contributions of membrane-bound
BAFF, soluble BAFF 3-mer and soluble BAFF 60-mer to the physiological functions of
BAFF. With the recent discovery that these forms likely engage different sets of
receptors, there is no doubt that the analysis of knock-in mice deficient for on or the other
forms of BAFF and APRIL will yield interesting information on how these ligands
control the various aspects of B cell biology they are implicated in.
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Figure legends
Figure 1: The complexity of the BAFF and APRIL system.
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Red arrowheads indicate furin consensus cleavage sites.  Glycosaminoglycan side chains
of proteoglycans are shown as thick wavy red lines. Two splicing isoforms of human
TACI differing in the presence or absence of the first cystein-rich domain are depicted.
Figure 2: Sequence alignment of BAFF, BALM and APRIL.
The alignment shows sequences of the C-terminal portions of BAFF, BALM and APRIL
of different species. β-strands as found in the crystal structure of human BAFF and
mouse APRIL are schematized above and below the alignment, respectively. Hs: Homo
sapiens (human). Mm: Mus musculus (mouse). Gg: Gallus gallus (chicken). Om:
Oncorhynchus mykiss (rainbow trout). Ga: Gasterosteus aculeatus (threespine
stickleback, a fish). The R-X-R/K-R furin consensus cleavage site is indicated (furin).
Black dots: residues that are located within 4Å of another ligand protomer: These
residues correspond roughly to residues involved in trimer formation. Gray squares:
residues that are located within 4Å of a receptor (BAFF-R or BCMA for human BAFF;
BCMA or TACI for mouse APRIL). These residues correspond roughly to those involved
in receptor binding. Black diamonds: residues that are located within 4Å of another
BAFF trimer. BAFF residues that are involved in trimer - trimer interactions for the
formation of BAFF 60-mer are shaded gray. Cystein residues in β-sheets E and F
involved in the formation of a disulfide bridge are shown in bold and linked by a bracket.
The residue A120 of mouse APRIL that can be alternatively spliced is indicated by an
arrow. The basic sequence of human and mouse APRIL involved in proteoglycan
interaction is underlined (basic seq). “*” between the furin site and β-sheet A of mouse
and trout BAFF indicate insertions of 29 and 20 amino acid residues, respectively.
Figure 3: Structural homology in the TNF family.
Ribbon representation of APRIL (mouse; pdb atomic coordinate file 1XU1), BAFF
(human; 1OQE), CD40L (human; 1ALY), EDA1 (human; 1RJ7), lymphotoxin-α
(human; LTα ; 1TNR), OX40L (mouse; 2HEW), RANKL (mouse; 1JTZ), TNF (human;
1TNF) and TRAIL (human; 1D4V). Structures are viewed along the three-fold symmetry
axis, which is highlighted in the structure of TRAIL. The unusually long DE loop of
BAFF is designated “flap”.
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Figure 4: Structure of BAFF 60-mer.
Upper left pictures: Two individual BAFF trimers linked or not by the flap region. Upper
middle picture: Space filling representation of BAFF 60-mer (1OTZ). Five trimers are
colored in warm tones, and the remaining 15 are shown in pale blue. Upper right picture:
Idem, but with 15 out of the 60 co-crystallized BAFF-R shown in green (1OTZ and
1POT). Bottom pictures: details of a trimer-trimer interaction, viewed from the center of
the 60-mer (1OTZ). BAFF 1 and FLAP 1 belong to a given BAFF trimer, while BAFF
1’, FLAP 1’ and BAFF 2’ belong to an adjacent BAFF trimer. Residues involved in three
distinct groups of interactions are shown (salt bridges 1, salt brides 2 and hydrophobic
core).
Figure 5: Model of APRIL bound to heparin and BCMA.
The structure of heparin (1FQ9) was manually positioned on that of the APRIL-BCMA
complex (1XU2). Side chains of all basic residues in the upper portion of APRIL are
shown in blue. In the side view (left picture), the BCMA-expressing cell would be at the
bottom of the figure. The orange ball is a nickel atom probably originating from the
purification process.
Figure 6: Sequence alignment of BCMA, TACI and BAFF-R.
β-sheets and helices found in the ligand-binding domain of human BAFF, human TACI
CRD2 and human BAFF-R are shown above the sequences. Connectivity of disulfide
bridges is indicated by brackets, and cystein residues are shown in bold. Both CRDs of
TACI are shown individually. The DxL motif that is crucial for ligand binding is shaded.
Figure 7: Determinants of ligand-binding specificity in BAFF-R, TACI and BCMA.
BAFF-R (1OQE; orange), TACI (1XU1; cyan) and BCMA (1OQD; purple) are shown
twice. The upper part of the figure shows residues determining binding specificity to
APRIL, and the lower part of the figure those residues important for binding to BAFF.
These residues were identified by shotgun alanine scanning (37, 39, 46). Side chains that
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are required for interactions are shown in green, whereas those that prevent or weaken
interactions are shown in red. Disulfide bridges are colored in yellow.
Figure 8: Receptor - ligand binding interfaces in the TNF family.
Structures of 6 complexes of a ligand co-crystallized with its receptor are shown. The
complexes are lymphotoxin-α/TNF-R1 (1TNR), TRAIL/DR5 (1DU3), OX40L/OX40
(2HEV), BAFF/BCMA (1OQD), BAFF/BAFF-R (1OQE) and APRIL/TACI (1XU1).
Receptors are shown as yellow ribbons, whereas ligands are shown in the space filling
representation, with one protomer in pale blue and another in pink. Ligand residues
within 4Å of the receptor are shown in blue and red. They provide an estimation of
residues involved in the interaction. In this representation, the transmembrane domain of
the receptors would be at the bottom of the figure.
Figure 9: Comparison of BAFF - BAFF-R and BAFF-R - TRAF3 complexes.
Structure of a BAFF trimer (golden ribbon) bound to BAFF-R (green surface; 1OQE) and
of the TRAF-binding sequence of the intracellular domain of BAFF-R (green surface)
bound to the C-terminal portion of TRAF3 (purple ribbons, 2GKW). The cell membrane
and the missing portion of BAFF-R are schematized as thick pink and green lines,
respectively.
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